

Marc H Scheetz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2917856/marc-h-scheetz-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200
papers

4,399
citations

39
h-index

57
g-index

222
ext. papers

5,499
ext. citations

4.9
avg, IF

5.73
L-index

#	Paper	IF	Citations
200	Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant Bloodstream Infections.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab651	1	1
199	Glomerular function and urinary biomarker changes between vancomycin and vancomycin plus piperacillin-tazobactam in a translational rat model.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , aac0213221	5.9	1
198	A Translational Rat Model to Assess Glomerular Function Changes with Vancomycin.. <i>International Journal of Antimicrobial Agents</i> , 2022 , 106583	14.3	0
197	Urinary Metabolomics from a Dose-Fractionated Polymyxin B Rat Model of Acute Kidney Injury.. <i>International Journal of Antimicrobial Agents</i> , 2022 , 106593	14.3	0
196	Vancomycin Pharmacokinetics in a Pregnancy Rat Model.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , e0005622	5.9	
195	In Vitro Nephrotoxicity and Permeation of Vancomycin Hydrochloride Loaded Liposomes. <i>Pharmaceutics</i> , 2022 , 14, 1153	6.4	0
194	Does renal function matter for polymyxin B?. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2629-2632	3.8	3
193	Vancomycin Duration of Therapy Can Inform the Need for Area Under the Curve Monitoring. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1235-e1236	11.6	0
192	Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 1525	4.5	2
191	Impact of early antimicrobial stewardship intervention in patients with positive blood cultures: results from a randomized comparative study: Impact of stewardship on BSI outcomes. <i>International Journal of Antimicrobial Agents</i> , 2021 , 59, 106490	14.3	
190	Antimicrobial never events: Objective application of a framework to assess vancomycin appropriateness. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 42, 1121-1123	2	
189	Microsampling Assays for Pharmacokinetic Analysis and Therapeutic Drug Monitoring of Antimicrobial Drugs in Children: A Critical Review. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 335-345	3.2	1
188	Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study. <i>Implementation Science Communications</i> , 2021 , 2, 34	2.2	2
187	Early Switch From Vancomycin to Daptomycin in Methicillin-Resistant Staphylococcus aureus Bacteremia: Still More Questions Than Answers. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1128-1129	11.6	1
186	The case for precision dosing: medical conservatism does not justify inaction. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1661-1665	5.1	4
185	Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling? 2021 , 3, e0446		10
184	Precision dosing of vancomycin: in defence of AUC-guided therapy in children. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2494-2497	5.1	1

183	Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum. <i>Journal of Applied Laboratory Medicine</i> , 2021 , 6, 1202-1212	2	2
182	The Pharmacodynamic-Toxicodynamic Relationship of AUC and in Vancomycin-Induced Kidney Injury in an Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	7
181	Supporting Precision Dosing in Drug Labeling. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 37-41	6.1	2
180	Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance. <i>Drug Discovery Today</i> , 2021 , 26, 31-43	8.8	16
179	A Critical Appraisal of the Effects of Anesthetics on Immune-system Modulation in Critically Ill Patients With COVID-19. <i>Clinical Therapeutics</i> , 2021 , 43, e57-e70	3.5	3
178	Targeting of Escherichia coli with Vancomycin-Arginine. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	6
177	Of Rats and Men: a Translational Model To Understand Vancomycin Pharmacokinetic/Toxicodynamic Relationships. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0106021	5.9	5
176	Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19. <i>EBioMedicine</i> , 2021 , 63, 103204	8.8	8
175	Cefepime precision dosing tool: From Standard to Precise Dose Using Nonparametric Population Pharmacokinetics.. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , AAC0204621	5.9	0
174	1090. Does calculation method matter for targeting vancomycin AUC?. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S636-S636	1	
173	Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational Rat Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	4
172	Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1575-1587	6.2	5
171	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1386-1388	2.4	56
170	Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review. <i>Journal of Global Antimicrobial Resistance</i> , 2020 , 21, 83-85	3.4	6
169	Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1027-1036	6.2	5
168	Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	8
167	Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1228-1236	5.1	18
166	Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention. <i>Pharmacotherapy</i> , 2020 , 40, 438-454	5.8	18

165	Exploring the Relationship between FEV Loss and Recovery and Aminoglycoside Pharmacokinetics in Adult Patients with Cystic Fibrosis: Implications for Clinical Dosing Strategies. <i>Pharmacotherapy</i> , 2020 , 40, 584-591	5.8	1
164	Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105970	14.3	2
163	β-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 429-433	5.1	25
162	Clinical Guideline Highlights for the Hospitalist: Therapeutic Monitoring of Vancomycin. <i>Journal of Hospital Medicine</i> , 2020 , 15, 740-742	2.7	0
161	238. Novel Way to Evaluate Antibiotic Use Appropriateness: Moving Towards the Never Event Classification by Electronic Algorithm. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S119-S120	1	
160	Development of ELISA Approach to Measure Kidney Injury Molecule-1. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
159	Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa538	1	13
158	Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction?. <i>Clinical Infectious Diseases</i> , 2020 , 71, 426-432	11.6	14
157	β-Lactam dosing strategies: Think before you push. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106151	14.3	3
156	A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , 2020 , 2, 491-495	3.5	3
155	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 561-572	6.2	15
154	The Emperor's New Clothes: Prospective Observational Evaluation of the Association Between Initial Vancomycin Exposure and Failure Rates Among Adult Hospitalized Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). <i>Clinical Infectious Diseases</i> , 2020 , 70, 1534-1545	11.6	54
153	Mechanisms of antimicrobial-induced nephrotoxicity in children. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1-13	5.1	25
152	Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1881-1887	11.6	63
151	Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	4
150	Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2326-2334	5.1	21
149	Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	23
148	A Review of the Clinical Pharmacokinetics of Polymyxin B. <i>Antibiotics</i> , 2019 , 8,	4.9	33

147	Vancomycin Prescribing and Therapeutic Drug Monitoring in Children With and Without Acute Kidney Injury After Cardiac Arrest. <i>Paediatric Drugs</i> , 2019 , 21, 107-112	4.2	4
146	Evaluation of Fetal and Maternal Vancomycin-Induced Kidney Injury during Pregnancy in a Rat Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	3
145	Writing and Thinking. <i>American Journal of Pharmaceutical Education</i> , 2019 , 83, 7785	2.5	
144	1335. A Translational Nephrotoxicity Model to Probe Acute Kidney Injury with Vancomycin and Piperacillin/Tazobactam. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S483-S483	1	78
143	1548. Characterizing Cefepime Neurotoxicity: Experience from a Tertiary Care Center Performing β -lactam Therapeutic Drug Monitoring. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S565-S565	1	78
142	1569. A Translational Model to Assess the Impact of Polymyxin B Dose Fractionation on Kidney Injury. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S573-S574	1	1
141	2000. Utilization of a Never Event Framework to Classify Antimicrobial Appropriateness. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S670-S671	1	78
140	2010. A Significant Reduction in Empiric Vancomycin Days of Therapy for Suspected MRSA Pneumonia in Adult Non-ICU Patients After Implementation of a Rapid MRSA Nasal PCR Test with Antimicrobial Stewardship Intervention. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S674-S675	1	1
139	1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S574-S575	1	78
138	Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible <i>Staphylococcus aureus</i> bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2019 , 53, 225-233	14.3	11
137	Understanding the Components, Calculation, and Impact of Monthly and Seasonal Variation of the Standardized Antimicrobial Utilization Ratio (SAAR). <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	1
136	Quantifying the importance of active antimicrobial therapy among patients with Gram-negative bloodstream infections: Cefepime as a representative agent. <i>International Journal of Antimicrobial Agents</i> , 2019 , 53, 95-97	14.3	3
135	It is time to define antimicrobial never events. <i>Infection Control and Hospital Epidemiology</i> , 2019 , 40, 206-207		6
134	Carbapenems vs. alternative β -lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 451-458	14.3	10
133	Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. <i>Clinical Microbiology and Infection</i> , 2018 , 24, 1070-1076	9.5	35
132	Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	42
131	Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	23
130	Effect of elevated imipenem/cilastatin minimum inhibitory concentrations on patient outcomes in Gram-negative bloodstream infections. <i>Journal of Global Antimicrobial Resistance</i> , 2018 , 13, 261-263	3.4	2

129	Measuring the impact of varying denominator definitions on standardized antibiotic consumption rates: implications for antimicrobial stewardship programmes. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2876-2882	5.1	3
128	Prevalence of a Cefazolin Inoculum Effect Associated with Gene Types among Methicillin-Susceptible <i>Staphylococcus aureus</i> Isolates from Four Major Medical Centers in Chicago. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	17
127	Preventing the Post-Antibiotic Era by Training Future Pharmacists as Antimicrobial Stewards. <i>American Journal of Pharmaceutical Education</i> , 2018 , 82, 6770	2.5	16
126	Correlation between hospital-level antibiotic consumption and incident health care facility-onset <i>Clostridium difficile</i> infection. <i>American Journal of Infection Control</i> , 2018 , 46, 270-275	3.8	6
125	Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 239-243	14.3	14
124	1391. Vancomycin Area Under the Curve (AUC) to Predict Nephrotoxicity: A Systematic Review and Meta-Analysis of Observational Studies. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S427-S427	1	78
123	1871. Identifying Time Periods of High and Low Vancomycin Use. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S535-S535	1	78
122	1821. Understanding the Components and Calculation of the SAAR, Illustrative Data. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S517-S518	1	78
121	209. Impact of a Risk-based CAP Prescribing Guideline Paired with Antimicrobial Stewardship to Improve Antibiotic Prescribing for Patients at Low Risk for Drug-Resistant Pathogens. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S91-S91	1	78
120	1419. 24-Hour Pharmacokinetic Relationships for Intravenous Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S437-S438	1	78
119	1394. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S429-S429	1	78
118	Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients. <i>Pharmacotherapy</i> , 2018 , 38, 730-738	5.8	24
117	Eight unexpected cases of vancomycin associated acute kidney injury with contemporary dosing. <i>Journal of Infection and Chemotherapy</i> , 2017 , 23, 326-332	2.2	4
116	Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest MIC values of 1.5mg/L: A pilot study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017 , 88, 259-263	2.9	14
115	Analysis of an Infectious Diseases Pharmacist on Call Pager Program to Inform Educational Efforts. <i>Journal of Pharmacy Technology</i> , 2017 , 33, 146-150	0.6	
114	A Simple Microsoft Excel Method to Predict Antibiotic Outbreaks and Underutilization. <i>Infection Control and Hospital Epidemiology</i> , 2017 , 38, 860-862	2	2
113	Critical Need for Clarity in Polymyxin B Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	11
112	Resolution of acyclovir-associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017 , 42, 350-355	2.2	12

111	Implementation of a ceftazidime-based stewardship pathway for methicillin-susceptible <i>Staphylococcus aureus</i> bloodstream infections paired with infectious diseases consultation. <i>International Journal of Antimicrobial Agents</i> , 2017 , 49, 650-654	14.3	6
110	Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate <i>Staphylococcus aureus</i> (hVISA) by Etest [®] macromethod among patients with MRSA bloodstream infections: a pilot study. <i>BMC Infectious Diseases</i> , 2017 , 17, 534	4	6
109	Engaging Pharmacy Students in Research Through Near-Peer Training. <i>American Journal of Pharmaceutical Education</i> , 2017 , 81, 6340	2.5	10
108	The Emperor's New Clothes: Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE). <i>Open Forum Infectious Diseases</i> , 2017 , 4, S30-S31	1	5
107	High-Performance Liquid Chromatography Method for Rich Pharmacokinetic Sampling Schemes in Translational Rat Toxicity Models With Vancomycin. <i>Clinical and Translational Science</i> , 2017 , 10, 496-502	4.9	8
106	24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	22
105	Factors contributing to vancomycin-resistant <i>Enterococcus</i> spp. horizontal transmission events: exploration of the role of antibacterial consumption. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017 , 89, 72-77	2.9	5
104	Defining the impact of severity of illness on time above the MIC threshold for ceftazidime in Gram-negative bacteraemia: a 'Goldilocks' window. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 487-490	14.3	13
103	Population pharmacokinetics of ceftazidime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 482-486	14.3	11
102	Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial. <i>BMC Infectious Diseases</i> , 2017 , 17, 401	4	7
101	Days of Therapy and Antimicrobial Days: Similarities and Differences Between Consumption Metrics. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 971-973	2	3
100	Impact of body mass index on clinical outcomes in patients with gram-negative bacteria bloodstream infections. <i>Journal of Infection and Chemotherapy</i> , 2016 , 22, 671-6	2.2	7
99	Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5742-51	5.9	42
98	Pharmacokinetics of centhaquin citrate in a dog model. <i>Journal of Pharmacy and Pharmacology</i> , 2016 , 68, 803-9	4.8	4
97	Investigating the Extremes of Antibiotic Use with an Epidemiologic Framework. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3265-9	5.9	7
96	Tree-Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the Horse. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 838-44	5.9	9
95	An exploratory analysis of the ability of a ceftazidime trough concentration greater than 22 mg/L to predict neurotoxicity. <i>Journal of Infection and Chemotherapy</i> , 2016 , 22, 78-83	2.2	19
94	Carbapenem susceptibility breakpoints, clinical implications with the moving target. <i>Expert Review of Anti-Infective Therapy</i> , 2016 , 14, 389-401	5.5	6

93	Periarrest intestinal bacterial translocation and resuscitation outcome. <i>Journal of Critical Care</i> , 2016 , 31, 217-20	4	13
92	Genome Sequences of Five Clinical Isolates of <i>Klebsiella pneumoniae</i> . <i>Genome Announcements</i> , 2016 , 4,		6
91	Implementing a Continuous or Prolonged Infusion Beta-Lactam Program in the Hospital Setting. <i>Methods in Pharmacology and Toxicology</i> , 2016 , 507-536	1.1	
90	Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 241-6	2.2	9
89	Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoietic Cell Transplantation. <i>Pharmacotherapy</i> , 2016 , 36, 1003-10	5.8	4
88	Pharmacokinetics of centhaquin citrate in a rat model. <i>Journal of Pharmacy and Pharmacology</i> , 2016 , 68, 56-62	4.8	5
87	Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature. <i>Journal of Infection and Chemotherapy</i> , 2015 , 21, 742-6	2.2	2
86	The association of elevated trough serum vancomycin concentrations with obesity. <i>Journal of Infection and Chemotherapy</i> , 2015 , 21, 507-11	2.2	15
85	Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015 , 82, 165-71	2.9	16
84	Development of a pharmacy student research program at a large academic medical center. <i>American Journal of Health-System Pharmacy</i> , 2015 , 72, 1885-9	2.2	6
83	Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible <i>Staphylococcus aureus</i> bloodstream infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5232-8	5.9	52
82	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1401-10	5.9	35
81	Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2068-73	5.1	30
80	Quantifying the clinical virulence of <i>Klebsiella pneumoniae</i> producing carbapenemase <i>Klebsiella pneumoniae</i> with a <i>Galleria mellonella</i> model and a pilot study to translate to patient outcomes. <i>BMC Infectious Diseases</i> , 2014 , 14, 31	4	54
79	Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. <i>Clinical Infectious Diseases</i> , 2014 , 59, 905-7	11.6	20
78	Impact of vancomycin treatment duration and dose on kidney injury. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 297-8	14.3	7
77	Reporting of Unit-Specific, Culture Site-Specific Antimicrobial Susceptibility for Gram-Negative Bacteria: Identification of Significant Differences in Susceptibility, Intervention to Guide Empiric Therapy and Impact on Antimicrobial Consumption. <i>Open Forum Infectious Diseases</i> , 2014 , 1, S367-S367	1	
76	Projections for anti-infective drug shortages and time to actual resolution. <i>American Journal of Health-System Pharmacy</i> , 2014 , 71, 2074-8	2.2	7

75	Knowledge and attitudes of doctor of pharmacy students regarding the appropriate use of antimicrobials. <i>Clinical Infectious Diseases</i> , 2014 , 59 Suppl 3, S162-9	11.6	51
74	Novel work models needed for faculty members trying to balance clinical practice with scholarly responsibilities. <i>American Journal of Pharmaceutical Education</i> , 2014 , 78, 21	2.5	2
73	Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-lactamase-producing <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3757-61	5.9	13
72	Developing a Method for Reporting Patient Harm Due to Antimicrobial Shortages. <i>Infectious Diseases and Therapy</i> , 2014 , 3, 349-55	6.2	6
71	Pathogenicity of clinical <i>Acinetobacter baumannii</i> isolates in a <i>Galleria mellonella</i> host model according to bla(OXA-40) gene and epidemiological outbreak status. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1240-2	5.9	6
70	Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals. <i>Pharmacotherapy</i> , 2013 , 33, 1256-63	5.8	47
69	Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project. <i>Drug Safety</i> , 2013 , 36, 335-47	5.1	14
68	Variability of cyclosporine concentrations by HPLC and TDX monoclonal assay methods, application of a correction factor, and description of a novel clinical approach to determine the practical consequences of changing assay technique. <i>Clinical Transplantation</i> , 2013 , 27, 154-61	3.8	2
67	Characterization of ciprofloxacin resistant <i>Escherichia coli</i> isolates among men undergoing evaluation for transrectal ultrasound guided prostate biopsy. <i>Journal of Urology</i> , 2013 , 190, 2026-32	2.5	17
66	Temporal changes in pulsed-field gel electrophoresis banding in vancomycin-resistant <i>Enterococcus faecium</i> and implications for outbreak investigations. <i>American Journal of Infection Control</i> , 2013 , 41, 349-53	3.8	5
65	Empty shelves, full of frustration: consequences of drug shortages and the need for action. <i>Hospital Pharmacy</i> , 2013 , 48, 617-8	1.1	3
64	Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 3969-75	5.9	45
63	Virulence of vancomycin-resistant <i>Enterococcus faecium</i> according to linezolid resistance and clinical outbreak status. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 3923-7	5.9	6
62	Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5131-3	5.9	116
61	Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5854-9	5.9	21
60	Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions. <i>American Journal of Health-System Pharmacy</i> , 2013 , 70, 1163-6 ^{2.2}		8
59	Effects on patient care caused by drug shortages: a survey. <i>Journal of Managed Care Pharmacy</i> , 2013 , 19, 783-8		71
58	Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. <i>Journal of Urology</i> , 2012 , 187, 1275-9	2.5	203

57	Prospective approach to managing antimicrobial drug shortages. <i>Infection Control and Hospital Epidemiology</i> , 2012 , 33, 745-52	2	20
56	Antimicrobial stewardship programs: methods of operation and suggested outcomes. <i>Expert Review of Anti-Infective Therapy</i> , 2012 , 10, 63-73	5.5	46
55	Effective use of a clinical decision-support system to advance antimicrobial stewardship. <i>American Journal of Health-System Pharmacy</i> , 2012 , 69, 1543-4	2.2	6
54	Need for standardization in assessing impact of antibiotic shortages on patient outcomes. <i>American Journal of Health-System Pharmacy</i> , 2012 , 69, 2129-30	2.2	2
53	The impact of anti-infective drug shortages on hospitals in the United States: trends and causes. <i>Clinical Infectious Diseases</i> , 2012 , 54, 684-91	11.6	39
52	Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4885-90	5.9	64
51	An analysis of the accuracy of physician-entered indications on computerized antimicrobial orders. <i>Infection Control and Hospital Epidemiology</i> , 2012 , 33, 1066-7	2	9
50	Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of <i>Acinetobacter baumannii</i> bloodstream infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 4844-9	5.9	61
49	Genetic Mechanisms of Antimicrobial Resistance of <i>Acinetobacter baumannii</i> . <i>Annals of Pharmacotherapy</i> , 2011 , 45, 218-28	2.9	26
48	Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model. <i>Pharmacotherapy</i> , 2011 , 31, 469-79	5.8	3
47	Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice. <i>International Journal of Clinical Pharmacy</i> , 2011 , 33, 537-42	2.3	1
46	Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration. <i>Annals of Pharmacotherapy</i> , 2011 , 45, e64	2.9	12
45	Biopsy-Proven Acute Tubular Necrosis due to Vancomycin Toxicity. <i>International Journal of Nephrology</i> , 2011 , 2011, 436856	1.7	18
44	Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 184-9	5.9	15
43	Evaluation of a potential clinical interaction between ceftriaxone and calcium. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1534-40	5.9	31
42	Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 460-5	5.9	44
41	Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2285-90	5.1	32
40	The Impact of Qualitative Respiratory Cultures on Mortality in Critically Ill Patients with Hospital-Acquired Pneumonia. <i>Hospital Pharmacy</i> , 2010 , 45, 624-633	1.1	

39	Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring. <i>Bone Marrow Transplantation</i> , 2010 , 45, 1352-6	4.4	32
38	Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients. <i>International Journal of Antimicrobial Agents</i> , 2010 , 36, 94-5	14.3	12
37	Cerebral spinal fluid penetration of tigecycline in a patient with <i>Acinetobacter baumannii</i> cerebritis. <i>Annals of Pharmacotherapy</i> , 2010 , 44, 582-6	2.9	29
36	Differences in clinical outcomes in patients with vancomycin-resistant enterococci according to linezolid susceptibility. <i>Pharmacotherapy</i> , 2010 , 30, 1221-8	5.8	7
35	Predictability of doripenem susceptibility in <i>Acinetobacter baumannii</i> isolates based on other carbapenem susceptibilities and bla OXA gene status. <i>Pharmacotherapy</i> , 2010 , 30, 354-60	5.8	11
34	Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2010 , 30, 562-84	5.8	56
33	Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. <i>Clinical Therapeutics</i> , 2010 , 32, 1713-9	3.5	55
32	Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1793-6	5.9	58
31	Significant publications on infectious diseases pharmacotherapy in 2008. <i>American Journal of Health-System Pharmacy</i> , 2009 , 66, 1726-34	2.2	9
30	Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 816-25	5.1	59
29	Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1074-9	5.9	34
28	Morbidity associated with <i>Pseudomonas aeruginosa</i> bloodstream infections. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009 , 64, 311-9	2.9	28
27	Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for <i>Pseudomonas aeruginosa</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2009 , 64, 465-7	2.9	7
26	Characterization of <i>Acinetobacter baumannii</i> genotypes recovered from patients with repeated colonization or infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009 , 65, 1-6	2.9	8
25	Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. <i>Drug Safety</i> , 2009 , 32, 147-58	5.1	32
24	The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. <i>American Journal of Therapeutics</i> , 2009 , 16, 508-11	1	63
23	Empiric antibiotic selection for infectious emergencies: bacterial pneumonia, meningitis and sepsis. <i>Drugs of Today</i> , 2009 , 45, 379-93	2.5	4
22	Posaconazole: an oral triazole with an extended spectrum of activity. <i>Annals of Pharmacotherapy</i> , 2008 , 42, 1429-38	2.9	39

21	Characterization of genetic diversity of carbapenem-resistant <i>Acinetobacter baumannii</i> clinical strains collected from 2004 to 2007. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 1106-9	9.7	51
20	Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant <i>Enterococcus faecium</i> strains parallels increasing linezolid consumption. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 2256-9	5.9	76
19	In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1621-6	5.9	79
18	Systematic review of piperacillin-induced neutropenia. <i>Drug Safety</i> , 2007 , 30, 295-306	5.1	35
17	Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. <i>Bone Marrow Transplantation</i> , 2007 , 39, 425-9	4.4	173
16	Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 1734-9	2.9	33
15	Syphilis. <i>BMJ, The</i> , 2007 , 334, 143-7	5.9	94
14	Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. <i>Transplantation</i> , 2007 , 83, 874-82	1.8	33
13	Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant <i>Staphylococcus aureus</i> pneumonia. <i>Pharmacotherapy</i> , 2006 , 26, 539-50	5.8	56
12	Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. <i>American Journal of Health-System Pharmacy</i> , 2006 , 63, 1346-60	2.2	15
11	Peritoneal fluid penetration of tigecycline. <i>Annals of Pharmacotherapy</i> , 2006 , 40, 2064-7	2.9	19
10	Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 3355-60	5.9	32
9	Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in <i>Enterococcus faecium</i> and <i>Enterococcus faecalis</i> . <i>Journal of Clinical Microbiology</i> , 2006 , 44, 1098-100	9.7	21
8	Adjustment of antimicrobial dosages for continuous venovenous hemofiltration based on patient-specific information. <i>Clinical Infectious Diseases</i> , 2006 , 42, 436-7; author reply 437-8	11.6	10
7	The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006 , 56, 407-13	2.9	7
6	Lack of effect of fluoroquinolone resistance on mortality in subjects with <i>Pseudomonas aeruginosa</i> bacteraemia. <i>Journal of Infection</i> , 2006 , 52, 105-10	18.9	7
5	Effect of on-call infectious-diseases pharmacists on antibiotic expenditures. <i>American Journal of Health-System Pharmacy</i> , 2005 , 62, 1967-8	2.2	2
4	In vivo synergy of daptomycin plus a penicillin agent for MRSA?. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 55, 398-9	5.1	9

- 3 Urinary biomarker and histopathological evaluation of vancomycin and piperacillin-tazobactam nephrotoxicity in comparison with vancomycin in a rat model and a confirmatory cellular model 1
- 2 Genomics of Aminoglycoside Resistance in *Pseudomonas aeruginosa* Bloodstream Infections at a United States Academic Hospital 4
- 1 What Every Steward Should Know About Pharmacokinetics and Pharmacodynamics 155-174